Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
09 01 2019
Historique:
received: 11 12 2018
accepted: 11 12 2018
entrez: 11 1 2019
pubmed: 11 1 2019
medline: 3 4 2020
Statut: epublish

Résumé

Alzheimer's disease (AD) is pathologically characterized by the accumulation of amyloid-β (Aβ) plaques, neurofibrillary tangles and widespread neuronal loss in the brain. In recent years, blood biomarkers have emerged as a realistic prospect to highlight accumulating pathology for secondary prevention trials. Neurofilament light chain (NfL), a marker of axonal degeneration, is robustly elevated in the blood of many neurological and neurodegenerative conditions, including AD. A strong relationship with cerebrospinal fluid (CSF) NfL suggests that these biomarker modalities reflect the same pathological process. Yet, the connection between blood NfL and brain tissue pathology has not been directly compared. In this study, longitudinal plasma NfL from cognitively healthy controls (n = 12) and AD participants (n = 57) were quantified by the Simoa platform. On reaching post-mortem, neuropathological assessment was performed on all participants, with additional frozen and paraffin-embedded tissue acquired from 26 participants for further biochemical (Aβ

Identifiants

pubmed: 30626432
doi: 10.1186/s40478-018-0649-3
pii: 10.1186/s40478-018-0649-3
pmc: PMC6327431
doi:

Substances chimiques

Neurofilament Proteins 0
neurofilament protein L 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5

Subventions

Organisme : Medical Research Council
ID : MR/L016397/1
Pays : United Kingdom
Organisme : Marianne and Marcus Wallenberg Foundation
ID : N/A
Pays : International

Références

J Neurol Sci. 1994 Apr;122(2):189-203
pubmed: 8021703
Dement Geriatr Cogn Dis Extra. 2017 Sep 28;7(3):309-317
pubmed: 29118783
Alzheimers Dement. 2007 Oct;3(4):385-97
pubmed: 19595959
Neurology. 2000 May 23;54(10):1960-4
pubmed: 10822437
Sci Rep. 2016 May 31;6:26801
pubmed: 27241045
Neurology. 2007 Dec 11;69(24):2197-204
pubmed: 17568013
Expert Rev Mol Diagn. 2017 Aug;17(8):761-770
pubmed: 28598205
J Nutr Health Aging. 2005 Sep-Oct;9(5):330-8
pubmed: 16222399
Neuropsychol Rev. 2003 Jun;13(2):79-92
pubmed: 12887040
Nature. 2018 Feb 8;554(7691):249-254
pubmed: 29420472
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
J Alzheimers Dis. 2017;59(4):1139-1152
pubmed: 28731443
Brain. 2006 Nov;129(Pt 11):3035-41
pubmed: 17012293
J Neurosci. 1986 Mar;6(3):650-60
pubmed: 2420946
Brain. 2006 Nov;129(Pt 11):3042-50
pubmed: 17071923
Brain. 2016 Nov 1;139(11):2983-2993
pubmed: 27694152
Alzheimers Res Ther. 2018 Jul 28;10(1):71
pubmed: 30055655
J Alzheimers Dis. 2018;64(s1):S271-S279
pubmed: 29758941
Alzheimers Dement. 2014 Nov;10(6):799-807.e2
pubmed: 25012867
Neurology. 2017 Mar 7;88(10):930-937
pubmed: 28179466
JAMA Neurol. 2016 Jan;73(1):60-7
pubmed: 26524180
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28373358
J Neurosci Res. 2001 Nov 1;66(3):510-6
pubmed: 11746370
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
Neurobiol Aging. 2015 Oct;36(10):2671-3
pubmed: 26234755
Lancet Neurol. 2017 Aug;16(8):601-609
pubmed: 28601473
J Alzheimers Dis. 2018;63(2):479-487
pubmed: 29630554
Neuron. 2016 Jul 6;91(1):56-66
pubmed: 27292537
Neuron. 2018 Mar 21;97(6):1284-1298.e7
pubmed: 29566794
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Alzheimers Dement. 2018 Jul;14(7):869-879
pubmed: 29580670
Brain. 2007 Sep;130(Pt 9):2320-6
pubmed: 17586559
EBioMedicine. 2015 Nov 22;3:135-140
pubmed: 26870824
Neurology. 2016 Oct 25;87(17):1827-1835
pubmed: 27694257
World J Biol Psychiatry. 2018 Jun;19(4):244-328
pubmed: 29076399
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578
JAMA Neurol. 2017 Sep 1;74(9):1073-1080
pubmed: 28692710
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Alzheimers Res Ther. 2013 Mar 28;5(2):9
pubmed: 23551972
Neurology. 2012 May 15;78(20):1568-75
pubmed: 22517093
Brain. 2007 Oct;130(Pt 10):e82
pubmed: 17615094

Auteurs

Nicholas J Ashton (NJ)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.
King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.

Antoine Leuzy (A)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

Yau Mun Lim (YM)

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.

Claire Troakes (C)

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.

Tibor Hortobágyi (T)

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
MTA-DE Cerebrovascular and Neurodegenerative Research Group, Department of Neurology, University of Debrecen, Debrecen, Hungary.

Kina Höglund (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

Dag Aarsland (D)

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK.
Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.

Simon Lovestone (S)

Department of Psychiatry, University of Oxford. Warneford Hospital, Oxford, UK.

Michael Schöll (M)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL|, London, UK.

Abdul Hye (A)

King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK. abdul.1.hye@kcl.ac.uk.
NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK. abdul.1.hye@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH